EDAP TMS S.A. develops and distributes minimally invasive medical devices for treating urological diseases globally via three segments - High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment's products treat urological and other clinical indications, including the treatment of prostate cancer with ultrasound-guided robotic HIFU devices. The company markets and sells its products via its direct sales organization, platform, and third-party distributors.